The European Circular Bioeconomy Fund (ECBF) aims to catalyze the transition towards a sustainable future by investing in biobased companies with high potential for innovation, favorable returns, and sustainable impact. Denmark has proven to be an attractive entrepreneurial ecosystem for the growth-stage venture capital fund and other experienced investors. The newest addition to the Fund’s portfolio is the Copenhagen-based Biosyntia. With the investment, ECBF joins Novo Seeds and Sofinnova Partners in the shareholder structure, as a leading investor in Biosyntia’s funding round of 11.5M EUR.
Biosyntia produces natural ingredients based on microbial fermentation processes. Using cutting-edge biotechnology and proprietary R&D tools and insights, the company is developing first-of-its-kind precision fermentation processes allowing the company to deliver natural ingredients at scale both affordably and sustainably. All products are natural, vegan and EU-sourced. Biosyntia already has commercial partnerships, including collaborations with large market players such as Givaudan and WACKER. The first product to be marketed is a bio-based biotin (vitamin B7) that can be used in food supplements, food and beauty products.
Biosyntia produces natural ingredients based on microbial fermentation processes. Using cutting-edge biotechnology and proprietary R&D tools and insights, the company is developing first-of-its-kind precision fermentation processes allowing the company to deliver natural ingredients at scale both affordably and sustainably. All products are natural, vegan and EU-sourced. Biosyntia already has commercial partnerships, including collaborations with large market players such as Givaudan and WACKER. The first product to be marketed is a bio-based biotin (vitamin B7) that can be used in food supplements, food and beauty products.